Novel therapeutics for treatment of various inflammatory airway conditions including chronic obstructive pulmonary disease (COPD).
- NOX2/ROS inhibitors have potential for use in a wide variety of clinical indications.
- Current treatments are weakly effective or provide only symptomatic relief for inflammatory airway diseases.
NADPH-oxidase 2 (NOX2) and reactive oxygen species (ROS) is currently an unestablished drug target. There are few NOX inhibitors in clincial trials. Emory scientists have developed three chemical series of novel NOX2/ROS inhibitors, with different NOX2/ROS isoform selectivities and therefore different uses for clinical indications. The inhibitors can be used for the treatment of inflammatory airway diseases such as COPD, acute respiratory distress syndrome, acute lung inflammation as well as hypertension, ischemia/reperfusion injury (including stroke, myocardial infarction, transplanted organs), diabetes, atherosclerosis, Alzheimer's disease, various cancers, Parkinson's disease, pulmonary fibrosis, liver fibrosis, cardiac hypertrophy, diabetic nephropathy, diabetic neuropathy, scar formation, skin aging and damage, psoriasis, and as an agent for preservation of organs during transplantation.
Lead identified and in vivo studies have been performed in mouse models of the flu and liver fibrosis.